References
- Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med 2010; 362(13):1169–1171.
- McMahon AW, Levenson MS, McEvoy BW, Mosholder AD, Murphy D. Age and risks of FDA-approved long-acting β2-Adrenergic receptor agonists. Pediatrics 2011; 128(5):e1147–e1154.
- FDA Drug Safety Communication: New safety requirements for long-acting inhaled asthma medications called long-acting beta-agonists (LABAs). 18 February 2010. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm200776.htm?sms_ss=email. Accessed February 8, 2012.
- FDA Drug Safety Communication: Drug labels now contain updated recommendations on the appropriate use of long-acting inhaled asthma medications called long-acting beta-agonists (LABAs). 2 June 2010. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213836.htm. Accessed February 8, 2012.
- ADVAIR® DISKUS® (fluticasone propionate and salmeterol inhalation powder): Prescribing information. GlaxoSmithKline 2006; Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021077s026lbl.pdf. Accessed February 8, 2012.
- SEREVENT® DISKUS® (salmeterol xinafoate inhalation powder): Prescribing information. GlaxoSmithKline 2006; Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020692s029lbl.pdf. Accessed February 8, 2012.
- BROVANA™ (arformoterol tartrate Inhalation Solution): Prescribing information. Sepracor Inc 2006; Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021912lbl.pdf. Accessed February 8, 2012.
- SYMBICORT® (budesonide and formoterol fumarate Inhalation Aerosol): prescribing information. AstraZeneca 2006; Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021929lbl.pdf. Accessed February 8, 2012.
- FORADIL® AEROLIZER® (formoterol fumarate inhalation powder): Prescribing Information. Novartis AG 2006; Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020831s009lbl.pdf. Accessed February 8, 2012.
- National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Institutes of Health; National Heart, Lung, and Blood Institute. NIH publication no. 07-4051. Available at: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf. Accessed August 28, 2007.
- Friedman H, Wilcox T, Reardon G, Crespi S, Yawn BP. A retrospective study of the use of fluticasone propionate/salmeterol combination as initial asthma controller therapy in a commercially insured population. Clin Ther 2008; 30:1908–1917.
- Stempel DA, Stoloff SW, Carranza Rosenzweig JR, Stanford RH, Ryskina KL, Legorreta AP. Adherence to asthma controller medication regimens. Respir Med 2005; 99(10):1263–1267.
- Blanchette CM, Culler SD, Ershoff D, Gutierrez B. Association between previous health care use and initiation of inhaled corticosteroid and long-acting beta2-adrenergic agonist combination therapy among US patients with asthma. Clin Ther 2009; 31:2574–2583.
- Ye X, Gutierrez B, Zarotsky V, Nelson M, Blanchette CM. Appropriate use of inhaled corticosteroid and long-acting beta(2)-adrenergic agonist combination therapy among asthma patients in a US commercially insured population. Curr Med Res Opin 2009; 25:2251–2258.
- Tan H, Sarawate C, Singer J, Elward K, Cohen RI, Smart BA, Busk MF, Lustig J, O’Brien JD, Schatz M. Impact of asthma controller medications on clinical, economic, and patient-reported outcomes. Mayo Clin Proc 2009; 84:675–684.
- Stephenson JJ, Quimbo RA, Gutierrez B. Subacute lack of asthma control as a predictor of subsequent acute asthma exacerbation in a managed care population. Am J Manag Care 2010; 16:108–114.
- Broder MS, Chang EY, Kamath T, Sapra S. Poor disease control among insured users of high-dose combination therapy for asthma. Allergy Asthma Proc 2010; 31:60–67.
- Cooper WO, Hickson GB. Corticosteroid prescription filling for children covered by Medicaid following an emergency department visit or a hospitalization for asthma. Arch Pediatr Adolesc Med 2001; 155:1111–1115.
- Friedman HS, Eid NS, Crespi S, Wilcox TK, Reardon G. Retrospective claims study of fluticasone propionate/salmeterol fixed-dose combination use as initial asthma controller therapy in children despite guideline recommendations. Clin Ther 2009; 31:1056–1063.
- Beauchesne MF, Chartier A, Fillion A, Lemière C, Lecompte S, Blais L. Asthma control score based on filled medication prescriptions: A validation study. Can Respir J 2008; 15:423–426.